← Human Trials & Peer-Reviewed Studies
Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism
Plain-language guide to PMID 9708607 (1998): crossover controlled clinical trial study of Parathyroid Hormone (PTH 1-84) in 25 patients, hyperparathyroidism.
Key Facts
- PMID
- 9708607
- Journal
- American journal of kidney diseases : the official journal of the National Kidney Foundation
- Year
- 1998
- Study type
- Controlled Clinical Trial
- Authors
- Akiba T et al. (10 authors)
- DOI
- 10.1053/ajkd.1998.v32.pm9708607
What This Study Did, in Plain Language
What Was Tested
Researchers studied Parathyroid Hormone (PTH 1-84) in the context of hyperparathyroidism in this controlled clinical trial publication.
Active vitamin D3 is extensively used for the treatment of secondary hyperparathyroidism in hemodialysis patients.
New modalities with higher specificity for PTH suppression are desirable.
Who Took Part
According to the abstract, 25 patients were involved.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
In this study, 25 hemodialysis patients with moderate to severe secondary hyperparathyroidism who had normal serum calcium levels were enrolled.
Based on serum calcium levels and intact PTH, the subjects were allocated into two groups, and a comparative study was conducted using unmasked crossover design of two drugs x two periods.
How the Study Was Run
The design is described as crossover.
In the crossover set-up each of the patients took both Parathyroid Hormone (PTH 1-84) and the comparison in turn, acting as their own control.
What Was Measured
Active vitamin D3 is extensively used for the treatment of secondary hyperparathyroidism in hemodialysis patients.
The subject headings attached to it are Biomarkers, Calcitriol, Calcium, Hydroxycholecalciferols, Hyperparathyroidism, Secondary, Parathyroid Hormone and Renal Dialysis.
What This Means in Plain Language
The paper is a crossover study of Parathyroid Hormone (PTH 1-84) in 25 patients in people with hyperparathyroidism.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 1998 (American journal of kidney diseases : the official journal of the National Kidney Foundation), a journal based in United States.
More context: the Parathyroid Hormone (PTH 1-84) compound page, Hyperparathyroidism research.
Our Notes on the Compound
Parathyroid Hormone (PTH 1-84): The 84-amino-acid hormone that raises blood calcium; full-length PTH (Natpara) has been used in hypoparathyroidism. Teriparatide is its 1-34 fragment.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.